BioCryst Pharmaceuticals BCRX Business Segments — Income Tax
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's business segments — income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's business segments — income tax?
- BioCryst Pharmaceuticals (BCRX) reported business segments — income tax of $1M in Q1 2026.
- How has BioCryst Pharmaceuticals's business segments — income tax changed year-over-year?
- BioCryst Pharmaceuticals's business segments — income tax increased by 38.3% year-over-year, from $726K to $1M.
- What is the long-term trend for BioCryst Pharmaceuticals's business segments — income tax?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's business segments — income tax has grown at a 8.9% compound annual growth rate (CAGR), from $2.73M to $3.53M.
- What does business segments — income tax mean?
- Represents the total tax liability incurred by the business segment based on its taxable income for the reporting period. This metric reflects the impact of jurisdictional tax regulations on the segment's bottom-line performance.